Plasma Metabolomics Identifies Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction
These results identify plasma signatures that are shared as well as potentially distinguish HFrEF and HFpEF. Metabolite markers for ketogenic metabolic re-programming were identified as unique signatures in the HFrEF group, possibly related to increased levels of BNP. Our results set the stage for future studies aimed at assessing selected metabolites as relevant biomarkers to guide HF phenotype-specific therapeutics.
Authors
- Ravindra C. Kodihalli (ORCID: https://orcid.org/0000-0001-8566-5658)
- Tiffany Hidalgo
- Rachel J. Roth Flach (ORCID: https://orcid.org/0000-0003-2754-828X)
- John D. Groarke (ORCID: https://orcid.org/0000-0002-5277-8696)
- Daniel P. Kelly (ORCID: https://orcid.org/0000-0002-3811-9491)
- Clarissa Shoffler (ORCID: https://orcid.org/0000-0002-9064-2378)
- Donald Bennett
- Iphigenia Tzameli
- Daniel James Rader (ORCID: https://orcid.org/0000-0002-9245-9876)
- Christopher Petucci
- Fawaz Naeem (ORCID: https://orcid.org/0000-0003-3788-7736)
- Cheryl Tow‐Keogh
- Teresa C. Leone
- Jessica Mancuso (ORCID: https://orcid.org/0009-0008-5422-5404)
Institutions
- Pfizer (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1002/ehf2.15285
- Citations
- 9
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 7.25
Funders
- Pfizer
- University of Pennsylvania
- Georgia Clinical and Translational Science Alliance
- University of Pennsylvania Health System
- National Institutes of Health
- Perelman School of Medicine, University of Pennsylvania
- National Cancer Institute
- National Center for Advancing Translational Sciences